

Edoardo G. Giannini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1689889/edoardo-g-giannini-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

298
papers

8,206
citations

47
h-index

82
g-index

335
ext. papers

9,647
ext. citations

5
avg, IF

5.71
L-index

#	Paper	IF	Citations
298	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment.. <i>Frontiers in Oncology</i> , 2022 , 12, 822507	5.3	0
297	Pharmacotherapies in eosinophilic esophagitis: state of the art.. <i>Minerva Gastroenterology</i> , 2022 , 68, 69-76	3	
296	EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis.. <i>Journal of Hepatology</i> , 2022 ,	13.4	11
295	Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment. <i>Gastrointestinal Disorders</i> , 2022 , 4, 77-83	0.8	
294	Eosinophilic esophagitis: novel concepts regarding pathogenesis and clinical manifestations. <i>Minerva Gastroenterologica E Dietologica</i> , 2021 ,	1.6	3
293	Obeticholic Acid Improves Aminotransferases Early during Treatment in Patients with Primary Biliary Cholangitis Not Responding to Ursodeoxycholic Acid: A Study in Clinical Practice. <i>Immuno</i> , 2021 , 1, 457-467		
292	The ITA.LI.CA Consortium: How multicentre collaboration helped shape the management of patients with hepatocellular carcinoma on the basis of real-world evidence. <i>Annals of Hepatology</i> , 2021 , 100564	3.1	0
291	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. <i>European Journal of Cancer</i> , 2021 , 158, 133-143	7.5	
290	Achalasia and Obstructive Motor Disorders Are Not Uncommon in Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1554-1563	6.9	14
289	Liver Resection for Patients with Intermediate Stage Hepatocellular Carcinoma: Beyond Rigid Staging Systems Towards a More Personalized Therapeutic Approach. <i>Journal of Gastrointestinal Surgery</i> , 2021 , 25, 1078-1079	3.3	1
288	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13542	4.6	5
287	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. <i>Cancers</i> , 2021 , 13,	6.6	7
286	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. <i>Cancers</i> , 2021 , 13,	6.6	1
285	Prevention Strategies for Esophageal Cancer-An Expert Review. <i>Cancers</i> , 2021 , 13,	6.6	3
284	Sleeve gastrectomy may double the risk of esophageal adenocarcinoma in morbidly obese patients. <i>Surgery for Obesity and Related Diseases</i> , 2021 , 17, 1029-1030	3	1
283	Immunoglobulin, nucleos(t)ide analogues and hepatitis B virus recurrence after liver transplant: A meta-analysis. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13575	4.6	1
282	Refractoriness to Treatment Suggests That Clinical Evaluation Should Go Beyond the Diagnosis of Reflux Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1077-1078	6.9	

281	Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach. <i>Nutrients</i> , 2021 , 13,	6.7	4
280	Elevated adherence to vaccination against SARS-CoV-2 among patients with Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2021 ,	1.5	3
279	Letter: predictive factors for treatment discontinuation in IBD-anti-TNF trough levels and anti-drug antibodies. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 536-537	6.1	1
278	Recalibrating survival prediction among patients receiving trans-arterial chemoembolization for hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021 , 2, 45-53	0.8	1
277	Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
276	Monofocal hepatocellular carcinoma: How much does size matter?. <i>Liver International</i> , 2021 , 41, 396-407	7.9	7
275	Applicability of Parameters for the Noninvasive Diagnosis of Esophageal Varices Needing Treatment to Hepatitis C Virus-Cured Patients. <i>Clinical Infectious Diseases</i> , 2021 , 72, 1862-1863	11.6	1
274	COVID-19 and liver disease: Not all evil comes to harm. <i>Liver International</i> , 2021 , 41, 237-238	7.9	5
273	The changing scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2021 , 41, 585-597	7.9	25
272	Effects of SARS-CoV-2 emergency measures on high-risk lesions detection: a multicentre cross-sectional study. <i>Gut</i> , 2021 , 70, 1241-1243	19.2	3
271	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021 , 10, 126-136	9.1	3
270	Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. <i>Cancers</i> , 2021 , 13,	6.6	2
269	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2021 , 13,	6.6	4
268	Proactive Measures Aimed at Improving Appropriateness of Use of Proton Pump Inhibitors in Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 410	6.9	
267	Procedure-related bleeding risk in patients with cirrhosis and severe thrombocytopenia. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13508	4.6	7
266	Bleeding events in lusutrombopag-treated thrombocytopenic patients. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13503	4.6	3
265	Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. <i>International Journal of Biological Markers</i> , 2021 , 36, 54-61	2.8	5
264	Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 ,	2.2	1

263	High acceptance rate of COVID-19 vaccination in liver transplant recipients. <i>Journal of Hepatology</i> , 2021 , 75, 483-484	13.4	1
262	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study. <i>Digestive and Liver Disease</i> , 2021 , 53, 1011-1019	3.3	6
261	Is there an 'ideal' diet for patients with NAFLD?. <i>European Journal of Clinical Investigation</i> , 2021 , e13659	4.6	2
260	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy 2021 , 9,		6
259	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. <i>Digestive and Liver Disease</i> , 2021 ,	3.3	2
258	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.. <i>Gut</i> , 2021 ,	19.2	8
257	Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 1044-1045	6.1	
256	Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?. <i>Nutrients</i> , 2020 , 12,	6.7	5
255	Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?. <i>Cancers</i> , 2020 , 12,	6.6	16
254	Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. <i>Digestive and Liver Disease</i> , 2020 , 52, 862-868	3.3	5
253	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020 , 40, 1467-1476	7.9	8
252	Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice. <i>Digestive and Liver Disease</i> , 2020 , 52, 792-793	3.3	
251	Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data. <i>Clinical and Experimental Gastroenterology</i> , 2020 , 13, 99-104	3.1	8
250	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. <i>Journal of Hepatology</i> , 2020 , 73, 593-602	13.4	28
249	Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. <i>Liver International</i> , 2020 , 40, 1408-1414	7.9	13
248	Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy. <i>Liver International</i> , 2020 , 40, 530-538	7.9	1
247	Outcomes of Liver Transplant for Adults With Wilson's Disease. <i>Liver Transplantation</i> , 2020 , 26, 507-516	4.5	7
246	Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV. <i>Annals of Hepatology</i> , 2020 , 19, 222-225	3.1	5

245	P465 Therapeutic drug monitoring in Crohn's disease patients, a comparison between homogeneous mobility shift assay and point of care method. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S412-S412	1.5	
244	Esophageal reflux hypersensitivity: Non-GERD or still GERD?. <i>Digestive and Liver Disease</i> , 2020 , 52, 1413-1420	3.4	7
243	Course of oesophageal varices and performance of noninvasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13231	4.6	5
242	Concerns related to COVID-19 pandemic among patients with inflammatory bowel disease and its influence on patient management. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13233	4.6	12
241	High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2019 , 54, 1220-1225	3.4	4
240	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Liver International</i> , 2019 , 39, 1478-1489	7.9	27
239	Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. <i>Scientific Reports</i> , 2019 , 9, 3781	4.9	9
238	Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 296-304	2.2	26
237	Acquired Hepatocerebral Degeneration in the Absence of Portosystemic Shunting. <i>Journal of Clinical Neurology (Korea)</i> , 2019 , 15, 128-129	1.7	1
236	A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients. <i>American Journal of Gastroenterology</i> , 2019 , 114, 364-365	0.7	1
235	A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease. <i>Nutrition</i> , 2019 , 67-68, 110542	4.8	18
234	Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics. <i>Cancers</i> , 2019 , 11,	6.6	13
233	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , 2019 , 11,	6.6	25
232	947 Lusutrombopag for Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Who Are Undergoing Planned Invasive Procedures: Pooled Safety Analysis of Bleeding-Related Adverse Events. <i>American Journal of Gastroenterology</i> , 2019 , 114, S550-S550	0.7	
231	Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand. <i>Liver Cancer</i> , 2019 , 8, 524-526	9.1	
230	Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. <i>Nutrients</i> , 2019 , 11,	6.7	27
229	Regression of Fibrosis After Direct-acting Antivirals Treatment of Patients with Hepatitis C Virus Cirrhosis: Transposability to Nondecompensated Patients. <i>Journal of Clinical and Experimental Hepatology</i> , 2019 , 9, 546	4.1	
228	Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. <i>European Journal of Clinical Investigation</i> , 2019 , 49, e13058	4.6	24

227	Successful DAA Treatment and Global Improvement in a Cirrhotic Patient with Concomitant HCV Infection and Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 591-593	4	3
226	Reproducibility and Transportability of the Absence of Incremental Infectious Adverse Events in Patients With Higher Anti-TNF Drug Levels. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, e73	4.5	2
225	The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin. <i>Journal of Gastroenterology</i> , 2019 , 54, 261-270	6.9	7
224	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Infection</i> , 2019 , 47, 141-168	5.8	
223	Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations. <i>Digestive and Liver Disease</i> , 2019 , 51, 173-174	3.3	2
222	Treatment of early stage chronic hepatitis C virus infection. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 519-524	3.8	4
221	Specific issues concerning the management of patients on the waiting list and after liver transplantation. <i>Liver International</i> , 2018 , 38, 1338-1362	7.9	10
220	Long-Term Follow-Up Study of Liver-Related Outcome After Bilio-Pancreatic Diversion in Patients with Initial, Significant Liver Damage. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 1946-1951	4	2
219	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. <i>Journal of Gastrointestinal Surgery</i> , 2018 , 22, 859-871	3.3	17
218	Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2018 , 50, 452-456	3.3	19
217	Letter: it is time to adopt new objective parameters to accurately identify patients with functional heartburn. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 107-108	6.1	1
216	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , 2018 , 68, 1232-1244	11.2	15
215	NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis. <i>Journal of Hepatology</i> , 2018 , 69, 972-973	13.4	3
214	Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases. <i>European Journal of Clinical Investigation</i> , 2018 , 48, e13002	4.6	8
213	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 626-634	18.8	60
212	Metabolic disorders across hepatocellular carcinoma in Italy. <i>Liver International</i> , 2018 , 38, 2028-2039	7.9	5
211	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , 2018 , 50, 1105-1114	3.3	26
210	Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients. <i>International Journal of Biological Markers</i> , 2018 , 33, 423-431	2.8	18

209	Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study. <i>Oncotarget</i> , 2018 , 9, 17483-17490	3.3	5
208	Improvement in Waldenström's Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals. <i>Annals of Hepatology</i> , 2018 , 17, 0-10	3.1	
207	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. <i>Hepatology</i> , 2018 , 67, 1784-1796	11.2	65
206	Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients. <i>Annals of Hepatology</i> , 2018 , 17, 830-835	3.1	16
205	Improvement in Waldenström's Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals. <i>Annals of Hepatology</i> , 2018 , 17, 1072-1077	3.1	2
204	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Journal of Hepatology</i> , 2018 , 68, 1153-1157	3.7	2
203	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Journal of Hepatology</i> , 2018 , 68, 695-712	4.8	3
202	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Digestive and Liver Disease</i> , 2018 , 50, 1133-1152	3.3	2
201	Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: The perfect storm. <i>Liver International</i> , 2018 , 38, 2101	7.9	1
200	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018 , 46, 607-615	5.8	7
199	A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. <i>Liver International</i> , 2017 , 37, 1157-1166	7.9	53
198	Noninvasive assessment of varices needing treatment in patients with advanced chronic liver disease: No one should be left behind. <i>Hepatology</i> , 2017 , 65, 2131	11.2	1
197	Common issues in the management of patients in the waiting list and after liver transplantation. <i>Digestive and Liver Disease</i> , 2017 , 49, 241-253	3.3	18
196	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017 , 67, 65-71	13.4	63
195	Adalimumab Therapy Rather than Azathioprine and Mesalamine is Able to Halt Crohn's Disease Progression after Resective Surgery and a Post-Hoc Analysis of a Prospective Randomized Study. <i>Gastroenterology</i> , 2017 , 152, S774	13.3	3
194	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 427-434	18.8	13
193	A Nodule, is a Nodule, is a Nodule: May Alpha-Fetoprotein Make the Difference?. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1340	0.7	1
192	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 160-168	6.1	58

191	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. <i>Liver International</i> , 2017 , 37, 423-433	7.9	34
190	Personalized treatment of patients with very early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017 , 66, 412-423	13.4	75
189	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2017 , 37, 259-270	7.9	50
188	Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lhann Index. <i>Digestive and Liver Disease</i> , 2017 , 49, 175-180	3.3	17
187	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017 , 12, e0185728	3.7	28
186	An independent validation of the mortality score for the short-term prognostic prediction in patients with chronic HCV infection and advanced liver disease. <i>Gut</i> , 2016 , 65, 183-4	19.2	
185	Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1240-1	6.1	2
184	Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies. <i>Health and Quality of Life Outcomes</i> , 2016 , 14, 49	3	2
183	Positive PET in a Patient With Esophageal Leiomyoma. <i>American Journal of Gastroenterology</i> , 2016 , 111, 767	0.7	2
182	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , 2016 , 48, 455-467	3.3	41
181	Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. <i>Journal of Hepatology</i> , 2016 , 65, 280-8	13.4	72
180	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2016 , 111, 70-7	0.7	42
179	Prognostic role of mean platelet volume in patients with cirrhosis. <i>Digestive and Liver Disease</i> , 2016 , 48, 409-13	3.3	9
178	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. <i>PLoS Medicine</i> , 2016 , 13, e1002006	11.6	81
177	Breath Tests to Assess Alcoholic Liver Disease. <i>Reviews on Recent Clinical Trials</i> , 2016 , 11, 185-90	1.2	2
176	A Liver Index and its Relationship to Indices of HCC Aggressiveness. <i>Journal of Integrative Oncology</i> , 2016 , 5,		22
175	Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 385-99	6.1	33
174	Years of life that could be saved from prevention of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 814-24	6.1	16

173	Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016 , 51, 1081-6	2.4	26
172	Portal vein thrombosis and chronic liver disease progression: The closer you look the more you see. <i>Hepatology</i> , 2016 , 63, 342-3	11.2	4
171	Education and Imaging. Hepatobiliary and Pancreatic: A rare cause of portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 11	4	1
170	A new approach to the use of α -fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. <i>British Journal of Cancer</i> , 2015 , 112, 69-76	8.7	49
169	12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies. <i>Digestive and Liver Disease</i> , 2015 , 47, 864-8	3.3	
168	Adalimumab trough levels and response to biological treatment in patients with inflammatory bowel disease: a useful cutoff in clinical practice. <i>American Journal of Gastroenterology</i> , 2015 , 110, 472-3 ^{0.7}		5
167	Therapeutic management of chronic hepatitis B in clinical practice: a region-wide survey. <i>Journal of Clinical Gastroenterology</i> , 2015 , 49, 228-34	3	4
166	Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 1301-8	4	4
165	Platelet Dysfunction: Status of Thrombopoietin in Thrombocytopenia Associated with Chronic Liver Failure. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 455-61	5.3	8
164	Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 469-80	3.4	6
163	Screening for hepatocellular carcinoma in chronic liver disease. <i>Annals of Internal Medicine</i> , 2015 , 162, 239-40	8	1
162	Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor. <i>Liver Transplantation</i> , 2015 , 21, 1250-8	4.5	9
161	Optimal management of constipation associated with irritable bowel syndrome. <i>Therapeutics and Clinical Risk Management</i> , 2015 , 11, 691-703	2.9	10
160	Hepatocellular Carcinoma Is the Most Frequent Final Diagnosis of Focal Liver Lesions Identified in a Cross-Sectional Evaluation of Patients with Chronic Liver Disease in Saudi Arabia. <i>Journal of Cancer Research</i> , 2015 , 2015, 1-4		1
159	Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database. <i>International Journal of Biological Markers</i> , 2015 , 30, e65-72	2.8	6
158	Economic assessment of eltrombopag in the treatment of thrombocytopenia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015 , 15, 713-20	2.2	3
157	Prognosis of untreated hepatocellular carcinoma. <i>Hepatology</i> , 2015 , 61, 184-90	11.2	117
156	BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. <i>Liver International</i> , 2015 , 35, 223-31	7.9	30

155	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. <i>Journal of Hepatology</i> , 2015 , 62, 617-24	13.4	129
154	Starry Liver: An Unexpected Diagnosis. <i>ACG Case Reports Journal</i> , 2015 , 2, 77-8	0.6	1
153	Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2015 , 24, 451-6	1.4	19
152	Epidemiological and clinical features of hepatitis delta in HBsAg-positive patients by HIV status. <i>Antiviral Therapy</i> , 2015 , 20, 193-7	1.6	3
151	Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. <i>Cancer</i> , 2014 , 120, 2150-7	6.4	45
150	Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency. <i>Digestive and Liver Disease</i> , 2014 , 46, 826-32	3.3	11
149	Accuracy of alpha-fetoprotein measurement in detection of hepatocellular carcinoma--1 more nail in the coffin. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 2138-9	6.9	2
148	Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. <i>Seminars in Oncology</i> , 2014 , 41, 252-8	5.5	28
147	Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters. <i>Seminars in Oncology</i> , 2014 , 41, 406-414	5.5	11
146	Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. <i>Gastroenterology</i> , 2014 , 146, 442-52.e1	13.3	101
145	Low alpha-fetoprotein HCC and the role of GGTP. <i>International Journal of Biological Markers</i> , 2014 , 29, e395-402	2.8	15
144	Significance of platelet and AFP levels and liver function parameters for HCC size and survival. <i>International Journal of Biological Markers</i> , 2014 , 29, e215-23	2.8	27
143	Eltrombopag in patients with chronic hepatitis C and thrombocytopenia. <i>Future Virology</i> , 2014 , 9, 9-20	2.4	
142	Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis. <i>Hepatology</i> , 2014 , 60, 1442	11.2	26
141	Improving survival of cirrhosis patients with hepatocellular carcinoma through application of standard of care. <i>Hepatology</i> , 2014 , 60, 1446-7	11.2	4
140	Prognostic prediction and identification of candidates for salvage liver transplantation among patients with early hepatocellular carcinoma. <i>Liver Transplantation</i> , 2014 , 20, 1150-1	4.5	2
139	Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014 , 61, 333-41	13.4	84
138	Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1927-33.e2	6.9	80

137	Platelet count and survival of patients with compensated cirrhosis and small hepatocellular carcinoma treated with surgery. <i>Hepatology</i> , 2014 , 59, 1649	11.2	4
136	Use of liver breath tests to assess severity of nonalcoholic fatty liver disease. <i>Reviews on Recent Clinical Trials</i> , 2014 , 9, 178-84	1.2	1
135	Hepatocellular carcinoma in patients without cirrhosis in Italy. <i>Digestive and Liver Disease</i> , 2013 , 45, 164-9	3.3	31
134	Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2013 , 45, 712-23	3.3	128
133	Which anticoagulant drug should be used to treat portal vein thrombosis in patients with chronic liver disease?. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 103	6.9	3
132	Eltrombopag in patients with chronic liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 669-784		11
131	Relationship between 13C-aminopyrine breath test and the MELD score and its long-term prognostic use in patients with cirrhosis. <i>Digestive Diseases and Sciences</i> , 2013 , 58, 3024-8	4	6
130	Feasibility of the cut-and-push method for removing large-caliber soft percutaneous endoscopic gastrostomy devices. <i>Nutrition in Clinical Practice</i> , 2013 , 28, 490-2	3.6	10
129	Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it?. <i>World Journal of Gastroenterology</i> , 2013 , 19, 8808-21	5.6	53
128	Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres. <i>Liver International</i> , 2013 , 33, 1420-7	7.9	12
127	Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. <i>Liver International</i> , 2013 , 33, 1594-600	7.9	42
126	Surveillance for hepatocellular carcinoma: just do it!. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1013-4	0.7	5
125	Adequate interval for hepatocellular carcinoma surveillance. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1174	0.7	1
124	Predicting the posttransplant prognosis of patients with hepatocellular carcinoma: what lies beneath alpha-fetoprotein?. <i>Liver Transplantation</i> , 2013 , 19, 1166-7	4.5	1
123	Resminostat in advanced hepatocellular carcinoma (HCC): Overall survival subgroup analysis of prognostic factors in the SHELTER trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15088-e15088	2.2	5
122	Peg-interferon alpha-2a and low-dose ribavirin for treatment of hepatitis C virus infection in patients with sickle-cell anemia in Saudi Arabia. <i>Annals of Saudi Medicine</i> , 2013 , 33, 610-3	1.6	1
121	Peripheral blood cytopenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. <i>Liver International</i> , 2012 , 32, 1113-9	7.9	24
120	The changing scenario of hepatocellular carcinoma over the last two decades in Italy. <i>Journal of Hepatology</i> , 2012 , 56, 397-405	13.4	75

119	Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. <i>Journal of Hepatology</i> , 2012 , 56, 1089-1096	13.4	48
118	TACE treatment in hepatocellular carcinoma: what should we do now?. <i>Journal of Hepatology</i> , 2012 , 57, 221-2	13.4	20
117	Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. <i>Hepatology</i> , 2012 , 56, 1371-9	11.2	94
116	Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. <i>New England Journal of Medicine</i> , 2012 , 367, 716-24	59.2	230
115	Comment to "Platelet count/spleen diameter ratio for non-invasive diagnosis of oesophageal varices: is it useful in compensated cirrhosis?". <i>Digestive and Liver Disease</i> , 2012 , 44, 965	3.3	
114	Ten-year outcome of radiofrequency thermal ablation for hepatocellular carcinoma: an Italian experience. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1588-9; author reply 1590	0.7	5
113	Effectiveness of α -fetoprotein for hepatocellular carcinoma surveillance: the return of the living-dead?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012 , 6, 441-4	4.2	11
112	Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 195-202	2.2	12
111	Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4115-4115	1.5	2
110	Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2012 , 21, 157-63	1.4	25
109	Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. <i>Lancet Oncology</i> , 2011 , 12, 654-62	21.7	114
108	IL28B rs12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 398-400	6.1	2
107	Epidemiology of thrombocytopenia in patients with chronic hepatitis C: more than meets the eye. <i>Journal of Viral Hepatitis</i> , 2011 , 18, 8-10	3.4	8
106	Relative decrease in the role played by hepatitis B virus infection in the aetiology of hepatocellular carcinoma during a 20-year period: a multicentre Italian study. <i>Liver International</i> , 2011 , 31, 192-6	7.9	5
105	Alpha-fetoprotein in hepatocellular carcinoma surveillance: wake not the dead. <i>Hepatology</i> , 2011 , 54, 376-7	11.2	9
104	Full-dose peginterferon Alfa-2a and low-dose ribavirin treatment of genotypes 1 and 4 chronic hepatitis C patients with end-stage renal disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011 , 9, 1004; author reply 1005	6.9	2
103	Use of the platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices in patients with schistosomiasis. <i>Saudi Journal of Gastroenterology</i> , 2011 , 17, 307-11	3	17
102	Small intestinal bacterial overgrowth and <i>Helicobacter pylori</i> : can they be cause of thrombocytopenia in patients with chronic liver disease?. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1171-2; author reply 1172	0.7	3

101	Final Results of Open-Label Treatment with Eltrombopag During ENABLE 1: A Study of Eltrombopag As An Adjunct for Antiviral Treatment of Hepatitis C Virus Associated with Thrombocytopenia. <i>Blood</i> , 2011 , 118, 2232-2232	2.2	4
100	Transarterial chemoembolization in Child-Pugh class B patients with hepatocellular carcinoma: between the devil and the deep blue sea. <i>Liver International</i> , 2010 , 30, 923-4; author reply 924-5	7.9	4
99	Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 493-501	6.1	27
98	Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 502-8	6.1	41
97	Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 1000-6	6.1	47
96	Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. <i>Gut</i> , 2010 , 59, 387-96	19.2	121
95	"Blessed are those who have not seen and yet have believed". <i>American Journal of Gastroenterology</i> , 2010 , 105, 227-8	0.7	
94	Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. <i>Clinical Gastroenterology and Hepatology</i> , 2010 , 8, 899-902; quiz e109	6.9	128
93	Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. <i>Journal of Hepatology</i> , 2010 , 53, 291-7	13.4	226
92	Patent paraumbilical vein-induced hepatic encephalopathy. <i>Clinical Gastroenterology and Hepatology</i> , 2010 , 8, A28	6.9	0
91	Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 563-8	3.4	16
90	Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 3193-9	4	11
89	Further insights into the causes of thrombocytopenia in chronic hepatitis C. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2010 , 19, 357-8	1.4	2
88	A Review on the Use of Eltrombopag in Patients with Advanced Liver Disease. <i>Clinical Medicine Therapeutics</i> , 2009 , 1, CMT.S2267		
87	Pro: Cirrhotic patients with small esophageal varices should undergo primary prophylaxis. <i>American Journal of Gastroenterology</i> , 2009 , 104, 2132-4	0.7	2
86	Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. <i>BMC Cancer</i> , 2009 , 9, 33	4.8	68
85	Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse. <i>Hepatology</i> , 2009 , 49, 1442-8	11.2	14
84	Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden. <i>Journal of Medical Virology</i> , 2009 , 81, 1882-6	19.7	13

83	External validation of the platelet count/spleen diameter ratio for the diagnosis of esophageal varices in hepatitis C virus-related cirrhosis. <i>Digestive Diseases and Sciences</i> , 2009 , 54, 654-60	4	40
82	Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. <i>Journal of Internal Medicine</i> , 2009 , 266, 537-46	10.8	24
81	HCV and fat: something is missing. <i>Journal of Hepatology</i> , 2009 , 50, 421-2; author reply 422-3	13.4	1
80	Hepatocellular carcinoma in patients with cryptogenic cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 580-5	6.9	43
79	A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: A region-wide survey in Italy. <i>Journal of Clinical Gastroenterology</i> , 2009 , 43, 1001-7	3	21
78	Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. <i>Journal of Clinical Gastroenterology</i> , 2009 , 43, 962-6	3	56
77	Is female sex a significant favorable prognostic factor in hepatocellular carcinoma?. <i>European Journal of Gastroenterology and Hepatology</i> , 2009 , 21, 1212-8	2.2	37
76	Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. <i>American Journal of Gastroenterology</i> , 2008 , 103, 267-75	0.7	42
75	Thrombocytopenia in liver disease. <i>Current Opinion in Hematology</i> , 2008 , 15, 473-80	3.3	68
74	Early and very early HCC. <i>Digestive and Liver Disease</i> , 2007 , 39, A36-A37	3.3	1
73	Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?. <i>American Journal of Gastroenterology</i> , 2007 , 102, 2448-57; quiz 2458	0.7	90
72	Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1022-31	0.7	47
71	Validation of a multivariate model predicting presence and size of varices. <i>Journal of Clinical Gastroenterology</i> , 2007 , 41, 609-15	3	49
70	Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome. <i>Nutrition</i> , 2006 , 22, 334-42	4.8	74
69	Eligibility criteria for antiviral therapy in HCV-positive patients: similar things to (almost) similar people. <i>American Journal of Gastroenterology</i> , 2006 , 101, 406-7	0.7	6
68	Platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study. <i>American Journal of Gastroenterology</i> , 2006 , 101, 2511-9	0.7	165
67	Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 1378-84	6.9	51
66	Can <i>Helicobacter pylori</i> eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. <i>Journal of Clinical Gastroenterology</i> , 2006 , 40, 515-20	3	12

65	A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice. <i>Journal of Clinical Gastroenterology</i> , 2006 , 40, 521-7	3	26
64	Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease. <i>Liver International</i> , 2006 , 26, 439-44	7.9	1
63	Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. <i>Journal of Internal Medicine</i> , 2006 , 260, 142-50	10.8	31
62	A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 23, 281-7	6.1	21
61	Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 23, 1055-65	6.1	142
60	Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastroesophageal reflux disease. <i>Digestive Diseases and Sciences</i> , 2006 , 51, 1602-6	4	6
59	A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms. <i>Digestive Diseases and Sciences</i> , 2006 , 51, 1904-9	4	23
58	Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease. <i>Liver International</i> , 2006 , 060224014707001	7.9	
57	¹³ C-galactose breath test and ¹³ C-aminopyrine breath test for the study of liver function in chronic liver disease. <i>Clinical Gastroenterology and Hepatology</i> , 2005 , 3, 279-85	6.9	37
56	Liver enzyme alteration: a guide for clinicians. <i>Cmaj</i> , 2005 , 172, 367-79	3.5	923
55	5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'?. <i>Digestive and Liver Disease</i> , 2005 , 37, 723-31	3.3	19
54	Application of the platelet count/spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis: a validation study based on follow-up. <i>Digestive and Liver Disease</i> , 2005 , 37, 779-85	3.3	64
53	Longitudinal modifications of the MELD score have prognostic meaning in patients with liver cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2005 , 39, 912-4	3	9
52	Influence of 1-week <i>Helicobacter pylori</i> eradication therapy with rabeprazole, clarithromycin, and metronidazole on ¹³ C-aminopyrine breath test. <i>Digestive Diseases and Sciences</i> , 2005 , 50, 1207-13	4	10
51	Non-invasive assessment of liver function: trying not to miss an opportunity. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 19, 827-8	6.1	
50	Reply to Farina ti et al.: classification of [Intermediate stage]untreated hepatocellular carcinoma patients: the neighbour's grass is not so green. <i>Journal of Internal Medicine</i> , 2004 , 256, 531-531	10.8	
49	A reappraisal of the Barcelona Clinic Liver Cancer model: natural history of untreated 'intermediate stage' hepatocellular carcinoma. <i>Journal of Internal Medicine</i> , 2004 , 256, 529-30; author reply 531	10.8	1
48	Can inclusion of serum creatinine values improve the Child-Turcotte-Pugh score and challenge the prognostic yield of the model for end-stage liver disease score in the short-term prognostic assessment of cirrhotic patients?. <i>Liver International</i> , 2004 , 24, 465-70	7.9	25

47	High ascitic fluid leptin levels in patients with decompensated liver cirrhosis and sterile ascites: relationship with TNF-alpha levels. <i>Digestive Diseases and Sciences</i> , 2004 , 49, 275-80	4	6
46	Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems. <i>Journal of Internal Medicine</i> , 2004 , 255, 399-408	10.8	23
45	Combined multichannel intraluminal impedance and pH-metry: a novel technique to improve detection of gastro-oesophageal reflux literature review. <i>Digestive and Liver Disease</i> , 2004 , 36, 565-9	3.3	69
44	¹³ C-breath tests and liver fibrosis. <i>European Review for Medical and Pharmacological Sciences</i> , 2004 , 8, 51-4	2.9	15
43	Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. <i>American Journal of Gastroenterology</i> , 2003 , 98, 2516-20	0.7	67
42	Noninvasive diagnosis of fibrosis: the truth is rarely pure and never simple. <i>Hepatology</i> , 2003 , 38, 1312-3; author reply 1313	11.2	25
41	<i>Helicobacter pylori</i> infection is associated with greater impairment of cytochrome P-450 liver metabolic activity in anti-HCV positive cirrhotic patients. <i>Digestive Diseases and Sciences</i> , 2003 , 48, 802-8 ⁴		18
40	Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients. <i>Liver International</i> , 2003 , 23, 12-8	7.9	37
39	Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 17, 1563-9	6.1	44
38	Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. <i>Gastroenterology</i> , 2003 , 125, 993-4; author reply 994-5	13.3	16
37	Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. <i>Gastroenterology</i> , 2003 , 125, 992-3; author reply 994-5	13.3	24
36	MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. <i>Gut</i> , 2003 , 52, 134-9	19.2	232
35	The metabolic syndrome: all criteria are equal, but some criteria are more equal than others. <i>Archives of Internal Medicine</i> , 2003 , 163, 2787-8; author reply 2788		15
34	Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. <i>Gut</i> , 2003 , 52, 1200-5	19.2	291
33	Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. <i>Archives of Internal Medicine</i> , 2003 , 163, 218-24		240
32	¹³ C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2002 , 16, 717-25	6.1	45
31	Surveillance for hepatocellular carcinoma in liver cirrhosis: have programmes improved because patients have?. <i>Gut</i> , 2002 , 51, 456-7	19.2	1
30	Intravenous immunoglobulin for recurrent <i>Clostridium difficile</i> diarrhoea. <i>Gut</i> , 2002 , 51, 456	19.2	50

29	Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma. <i>Age and Ageing</i> , 2002 , 31, 457-62	3	11
28	Surveillance for hepatocellular carcinoma in liver cirrhosis: have programmes improved because patients have?. <i>Gut</i> , 2002 , 51, 611	19.2	
27	The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis. <i>American Journal of Gastroenterology</i> , 2002 , 97, 2855-60	7	47
26	Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. <i>Journal of Hepatology</i> , 2002 , 37, 572-7	13.4	86
25	Monitoring of liver metabolic function during interferon-alpha therapy and its relationship to treatment outcome in chronic hepatitis C patients. <i>Hepato-Gastroenterology</i> , 2002 , 49, 778-82		
24	Impairment of cytochrome P-450-dependent liver activity in cirrhotic patients with Helicobacter pylori infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2001 , 15, 1967-73	6.1	11
23	Long-term follow up of chronic hepatitis C patients after alpha-interferon treatment: a functional study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001 , 16, 399-405	4	9
22	Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage. <i>Digestive Diseases and Sciences</i> , 2001 , 46, 524-9	4	22
21	Chronic hepatitis C in different populations: similar patterns of alanine aminotransferase alteration characterize similar clinical subgroups. <i>Hepatology</i> , 2001 , 33, 313	11.2	
20	Leptin in nonalcoholic steatohepatitis: is it one of the "hits"?. <i>American Journal of Gastroenterology</i> , 2001 , 96, 2519-20	0.7	3
19	Transportability and reproducibility of the AST/ALT ratio in chronic hepatitis C patients. <i>American Journal of Gastroenterology</i> , 2001 , 96, 918-9	0.7	19
18	Leptin in nonalcoholic steatohepatitis: is it one of the hits?. <i>American Journal of Gastroenterology</i> , 2001 , 96, 2519-2520	0.7	2
17	Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy?. <i>Journal of Hepatology</i> , 2001 , 35, 432-3	13.4	24
16	Serum (LPTS) and ascitic leptin (LPTA) levels in decompensated cirrhotic patients. <i>Journal of Hepatology</i> , 2001 , 34, 202	13.4	4
15	Liver iron accumulation in chronic hepatitis C patients without HFE mutations: relationships with histological damage, viral load and genotype and alpha-glutathione S-transferase levels. <i>European Journal of Gastroenterology and Hepatology</i> , 2001 , 13, 1355-61	2.2	20
14	Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2001 , 13, 137-41	2.2	14
13	Utility of alpha-glutathione S-transferase assessment in chronic hepatitis C patients with near normal alanine aminotransferase levels. <i>Clinical Biochemistry</i> , 2000 , 33, 297-301	3.5	13
12	Oral or intravenous lidocaine administration to perform megx test?. <i>Digestive Diseases and Sciences</i> , 2000 , 45, 1011-2	4	

11	Is aspartate aminotransferase enough?. <i>American Journal of Gastroenterology</i> , 2000 , 95, 3687-8	0.7	
10	Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2000 , 95, 3211-7	0.7	48
9	Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens. <i>American Journal of Gastroenterology</i> , 2000 , 95, 2762-7	0.7	12
8	Is there a role for multiple quantitative liver function tests?. <i>Digestive and Liver Disease</i> , 2000 , 32, 644	3.3	1
7	Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. <i>Journal of Hepatology</i> , 2000 , 33, 33-7	13.4	109
6	The monoethylglycinexylidide test does not impair psychometric performance in patients with chronic hepatitis or cirrhosis. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 371-4	3.2	2
5	Histologic determinants of monoethylglycinexylidide formation in patients with chronic hepatitis C. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 455-9	3.2	3
4	Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients. <i>Liver International</i> , 1999 , 19, 432-7	7.9	43
3	Progressive liver functional impairment is associated with an increase in AST/ALT ratio. <i>Digestive Diseases and Sciences</i> , 1999 , 44, 1249-53	4	147
2	Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis?. <i>European Journal of Gastroenterology and Hepatology</i> , 1999 , 11, 559-63	2.2	30
1	Chronic liver disease related to hepatitis C virus: age of patients seems to be a determinant of severity independently of viral genotype. <i>European Journal of Gastroenterology and Hepatology</i> , 1999 , 11, 553-8	2.2	9